50 results on '"Gerardi, Viviana"'
Search Results
2. Can microbiota analysis help intercept cases of colon cancer in case of occult blood negativity, also suggesting possible pharmacological intervention strategies?
3. Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study
4. Can microbiota analysis help intercept cases of colon cancer in case of occult blood negativity, also suggesting possible pharmacological intervention strategies?
5. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey
6. Can the analysis of the gut microbiota have a clinical application in real life?
7. Crucial Additional Value of Enteroscopy in the Diagnosis, Assessment, and Further Management of Small Bowel Crohn’s Disease
8. Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice
9. Tu1568: THE EFFECTS OF LONG-TERM PROTON PUMP INHIBITOR THERAPY ON GUT MICROBIOTA - A SINGLE-CENTER EXPERIENCE
10. Tu1569: A POSSIBLE GUT MICROBIOTA SIGNATURE IN PATIENT WITH BLOATING: RESULTS FROM REAL LIFE
11. Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn’s disease: new prospective roles of CT enterography
12. Coeliac disease: an old or a new disease? History of a pathology
13. sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care
14. BENEFITS FROM A COMPUTER-AIDED DETECTION DEVICE IN COLONOSCOPY (ACCENDO-COLO) – AN INTERIM ANALYSIS OF AN ITALIAN MULTICENTER RANDOMIZED CLINICAL TRIAL
15. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
16. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care
17. Can We Predict the Efficacy of Anti-TNF-α Agents?
18. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
19. Mo1778 The Toll-Like-Receptor 9 Agonist DIMS0150 Demonstrates Therapeutic Efficacy for the Patient Reported Outcome Measures PRO-2 and Clinpro in Moderate to Severe Active Ulcerative Colitis
20. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
21. Infliximab does not increase colonic cancer risk associated to murine chronic colitis
22. Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?
23. Role and mechanisms of action ofEscherichia coliNissle 1917 in the maintenance of remission in ulcerative colitis patients: An update
24. Diagnosis and treatment of small intestinal bacterial overgrowth
25. Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility
26. Tu1302 Anti-TNF-α Induction Regimen Modulates Gut Microbiota Molecular Composition While Inducing Clinical Response in Crohn's Disease Patients: Toward a Personalized Medicine
27. Tu1363 An Open-Label, Pilot Study to Assess Feasibility and Safety of Fecal Microbiota Transplantation in Patients With Mild-Moderate Ulcerative Colitis: Preliminary Results
28. Tu1326 Topical Administration of the Toll-Like Receptor 9 Agonist DIMS0150 Provides Evidence for Efficacy in Moderate to Severe Ulcerative Colitis Treated in the Clinical Study Collect
29. Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn’s disease: new prospective roles of CT enterography
30. Tu1060 Role of CagA-Positive Strains of H. pylori in Acute Myocardial Infarction With ST-Segment Elevation
31. Mo1193 Infliximab Is Not Increasing Colonic Cancer Risk in Experimental IBD
32. Sa1344 Study of Gastric Emptying and Digestive Function With 13C Octanoic Acid Breath Test in Non Dyspeptic Healthy Volunteers
33. Role ofHelicobacter pyloriinfection on nutrition and metabolism
34. Sa1696 Effect of Bacillus Clausii in the N-Methylnitrosurea Induced Animal Model of Colorectal Cancer
35. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.
36. Diagnosis and treatment of small intestinal bacterial overgrowth.
37. The Gut Barrier
38. Su1195 The Prevalence of “H2 Non Producer” in IBS Population
39. Mo2017 Direct Effects of Infliximab (IFX) on Intestinal Mucosa: Exploring Mechanisms of Mucosal Healing
40. Sa1851 CT Enterography Correlation With Clinical Response to Therapy in Patients Affected by Crohn's Disease
41. Su1943 Correlation Between Gas Production and Intensity of Gastrointestinal Symptoms During Lactose Breath Test
42. Su1714 High Dose Amoxicillin-Based First Line Regimen Compared to Sequential Therapy in the Eradication of H. pylori Infection
43. Su1197 The Impact of Anxiety on Lactose Intolerance Symptoms
44. Effects of Infliximab (IFX) on Intestinal Epithelial Cells: Exploring Mechanisms of Mucosal Healing
45. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study
46. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
47. [The relationship between gut microbiota and cardiovascular diseases].
48. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
49. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment.
50. The gut barrier: new acquisitions and therapeutic approaches.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.